[1] C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O’Callaghan, D. Tu, N. C. Tebbutt, et al., K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N. Engl. J. Med. 359 (2008) 1757–1765.
[2] L.C. Ye, T.S. Liu, L. Ren, Y. Wei, D.X. Zhu, S.Y. Zai, et al., Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases, J. Clin. Oncol. 31 (2013) 1931–1938.
[3] J. Canon, K. Rex, A.Y. Saiki, C. Mohr, K. Cooke, D. Bagal, et al., The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity, Nature 575 (2019) 217–223.
[4] J. Guinney, R. Dienstmann, X. Wang, A. de Reyni`es, A. Schlicker, C. Soneson, et al., The consensus molecular subtypes of colorectal cancer, Nat. Med. 21 (2015) 1350–1356.
[5] E. White, Exploiting the bad eating habits of Ras-driven cancers, Genes Dev. 27 (2013) 2065–2071.
[6] A.C. Kimmelman, Metabolic dependencies in RAS-driven cancers, Clin. Canc. Res. 21 (2015) 1828–1834.
[7] J. Son, C.A. Lyssiotis, H. Ying, X. Wang, S. Hua, M. Ligorio, et al., Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway, Nature 496 (2013) 101–105.
[8] K. Kawada, K. Toda, Y. Sakai, Targeting metabolic reprogramming in KRAS-driven cancers, Int. J. Clin. Oncol. 22 (2017) 651–659.
[9] D.R. Wise, C.B. Thompson, Glutamine addiction: a new therapeutic target in cancer, Trends Biochem. Sci. 35 (2010) 427–433.
[10] Y.D. Bhutia, E. Babu, S. Ramachandran, V. Ganapathy, Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs, Canc. Res. 75 (2015) 1782–1788.
[11] E. Bernfeld, D.A. Foster, Glutamine as an essential amino acid for KRas-driven cancer cells, Trends Endocrinol. Metabol. 30 (2019) 357–368.
[12] K. Toda, K. Kawada, M. Iwamoto, S. Inamoto, T. Sasazuki, S. Shirasawa, et al., Metabolic alterations caused by KRAS mutations in colorectal cancer contribute to cell adaptation to glutamine depletion by upregulation of asparagine synthetase, Neoplasia 18 (2016) 654–665.
[13] H. Li, S. Ning, M. Ghandi, G.V. Kryukov, S. Gopal, A. Deik, et al., The landscape of cancer cell line metabolism, Nat. Med. 25 (2019) 850–860.
[14] M.V. Recouvreux, C. Commisso, Macropinocytosis: a metabolic adaptation to nutrient stress in cancer, Front. Endocrinol. 8 (2017) 261.
[15] D. Bar-Sagi, J.R. Feramisco, Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins, Science 233 (1986) 1061–1068.
[16] A. Veithen, P. Cupers, P. Baudhuin, P.J. Courtoy, v-Src induces constitutive macropinocytosis in rat fibroblasts, J. Cell Sci. 109 (1996) 2005–2012.
[17] W. Palm, J. Araki, B. King, R.G. DeMatteo, C.B. Thompson, Critical role for PI3- kinase in regulating the use of proteins as an amino acid source, Proc. Natl. Acad. Sci. U. S. A. 114 (2017) E8628–E8636.
[18] W. Palm, Y. Park, K. Wright, N.N. Pavlova, D.A. Tuveson, C.B. Thompson, The utilization of extracellular proteins as nutrients is suppressed by mTORC1, Cell 162 (2015) 259–270.
[19] S.M. Kim, T.T. Nguyen, A. Ravi, P. Kubiniok, B.T. Finicle, V. Jayashankar, et al., PTEN deficiency and AMPK activation promote nutrient scavenging and anabolism in prostate cancer cells, Canc. Discov. 8 (2018) 866–883.
[20] C. Commisso, S.M. Davidson, R.G. Soydaner-Azeloglu, S.J. Parker, J.J. Kamphorst, S. Hackett, et al., Macropinocytosis of protein is an amino acid supply route in Ras- transformed cells, Nature 497 (2013) 633–637.
[21] J.J. Kamphorst, M. Nofal, C. Commisso, S.R. Hackett, W. Lu, E. Grabocka, et al., Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein, Canc. Res. 75 (2015) 544–553.
[22] S.M. Davidson, O. Jonas, M.A. Keibler, H.W. Hou, A. Luengo, J.R. Mayers, et al., Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors, Nat. Med. 23 (2017) 235–241.
[23] L. Seguin, M.F. Camargo, H.I. Wettersten, S. Kato, J.S. Desgrosellier, T. von Schalscha, et al., Galectin-3, a druggable vulnerability for KRAS-addicted cancers, Canc. Discov. 7 (2017) 1464–1479.
[24] H. Tajiri, T. Uruno, T. Shirai, D. Takaya, S. Matsunaga, D. Setoyama, et al., Targeting ras-driven cancer cell survival and invasion through selective inhibition of DOCK1, Cell Rep. 19 (2017) 969–980.
[25] S. Shirasawa, M. Furuse, N. Yokoyama, T. Sasazuki, Altered growth of human colon cancer cell lines disrupted at activated Ki-ras, Science 260 (1993) 85–88.
[26] I. Baba, S. Shirasawa, R. Iwamoto, K. Okumura, T. Tsunoda, M. Nishioka, et al., Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells, Canc. Res. 60 (2000) 6886–6889.
[27] K. Aoki, M. Matsuda, Visualization of small GTPase activity with fluorescence resonance energy transfer-based biosensors, Nat. Protoc. 4 (2009) 1623–1631.
[28] R. Mizuno, Y. Kamioka, K. Kabashima, M. Imajo, K. Sumiyama, E. Nakasho, et al., In vivo imaging reveals PKA regulation of ERK activity during neutrophil recruitment to inflamed intestines, J. Exp. Med. 211 (2014) 1123–1136.
[29] H. Maekawa, H. Miyoshi, T. Yamaura, Y. Itatani, K. Kawada, Y. Sakai, et al., A chemosensitivity study of colorectal cancer using xenografts of patient-derived tumor-initiating cells, Mol. Canc. Therapeut. 17 (2018) 2187–2196.
[30] T. Yamamoto, H. Miyoshi, F. Kakizaki, H. Maekawa, T. Yamaura, T. Morimoto, et al., Chemosensitivity of patient-derived cancer stem cells identifies colorectal cancer patients with potential benefit from FGFR inhibitor therapy, Cancers (Basel) 12 (2020) 2010.
[31] C. Commisso, R.J. Flinn, D. Bar-Sagi, Determining the macropinocytic index of cells through a quantitative image-based assay, Nat. Protoc. 9 (2014) 182–192.
[32] A.I. Ivanov, Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol. Biol. 440 (2008) 15–33.
[33] M. Koivusalo, C. Welch, H. Hayashi, C.C. Scott, M. Kim, T. Alexander, et al., Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling, J. Cell Biol. 188 (2010) 547–563.
[34] H. Miyoshi, T.S. Stappenbeck, In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture, Nat. Protoc. 8 (2013) 2471–2482.
[35] H. Miyoshi, H. Maekawa, F. Kakizaki, T. Yamaura, K. Kawada, Y. Sakai, et al., An improved method for culturing patient-derived colorectal cancer spheroids, Oncotarget 9 (2018) 21950–21964.
[36] T. Yamaura, H. Miyoshi, H. Maekawa, T. Morimoto, T. Yamamoto, F. Kakizaki, et al., Accurate diagnosis of mismatch repair deficiency in colorectal cancer using high-quality DNA samples from cultured stem cells, Oncotarget 9 (2018) 37534–37548.
[37] A.J. Ridley, H.F. Paterson, C.L. Johnston, D. Diekmann, A. Hall, The small GTP- binding protein rac regulates growth factor-induced membrane ruffling, Cell 70 (1992) 401–410.
[38] W.K. Chan, P.L. Lorenzi, A. Anishkin, P. Purwaha, D.M. Rogers, S. Sukharev, et al., The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells, Blood 123 (2014) 3596–3606.
[39] U.K. Narta, S.S. Kanwar, W. Azmi, Pharmacological and clinical evaluation of L- asparaginase in the treatment of leukemia, Crit. Rev. Oncol. Hematol. 61 (2007) 208–221.
[40] G. Redelman-Sidi, A. Binyamin, I. Gaeta, W. Palm, C.B. Thompson, P.B. Romesser, et al., The canonical Wnt pathway drives macropinocytosis in cancer, Canc. Res. 78 (2018) 4658–4670.
[41] N. Tejeda-Mun˜oz, L.V. Albrecht, M.H. Bui, E.M. De Robertis, Wnt canonical pathway activates macropinocytosis and lysosomal degradation of extracellular proteins, Proc. Natl. Acad. Sci. U. S. A. 116 (2019) 10402–10411.
[42] E. Michalopoulou, F.R. Auciello, V. Bulusu, D. Strachan, A.D. Campbell, J. Tait- Mulder, et al., Macropinocytosis renders a subset of pancreatic tumor cells resistant to mTOR inhibition, Cell Rep. 30 (2020) 2729–2742.
[43] S.W. Lee, Y. Zhang, M. Jung, N. Cruz, B. Alas, C. Commisso, EGFR-pak signaling selectively regulates glutamine deprivation-induced macropinocytosis, Dev. Cell 50 (2019) 381–392.
[44] J.D. Rabinowitz, E. White, Autophagy and metabolism, Science 330 (2010) 1344–1348.
[45] J.Y. Guo, H.Y. Chen, R. Mathew, J. Fan, A.M. Strohecker, G. Karsli-Uzunbas, et al., Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis, Genes Dev. 25 (2011) 460–470.
[46] C.G. Kinsey, S.A. Camolotto, A.M. Boespflug, K.P. Guillen, M. Foth, A. Truong, et al., Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers, Nat. Med. 25 (2019) 620–627.
[47] K.L. Bryant, C.A. Stalnecker, D. Zeitouni, J.E. Klomp, S. Peng, A.P. Tikunov, et al., Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer, Nat. Med. 25 (2019) 628–640.
[48] J. Zhang, J. Fan, S. Venneti, J.R. Cross, T. Takagi, B. Bhinder, et al., Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion, Mol. Cell 56 (2014) 205–218.
[49] N.N. Pavlova, S. Hui, J.M. Ghergurovich, J. Fan, A.M. Intlekofer, R.M. White, et al., As extracellular glutamine levels decline, asparagine becomes an essential amino acid, Cell Metabol. 27 (2018) 428–438.
[50] A.S. Krall, S. Xu, T.G. Graeber, D. Braas, H.R. Christofk, Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor, Nat. Commun. 7 (2016) 11457.
[51] S.R.V. Knott, E. Wagenblast, S. Khan, S.Y. Kim, M. Soto, M. Wagner, et al., Asparagine bioavailability governs metastasis in a model of breast cancer, Nature 554 (2018) 378–381.
[52] D.M. Gwinn, A.G. Lee, M. Briones-Martin-Del-Campo, C.S. Conn, D.R. Simpson, A. I. Scott, et al., Oncogenic KRAS regulates amino acid homeostasis and asparagine biosynthesis via ATF4 and alters sensitivity to L-asparaginase, Canc. Cell 33 (2018) 91–107.
[53] M.N. Balasubramanian, E.A. Butterworth, M.S. Kilberg, Asparagine synthetase: regulation by cell stress and involvement in tumor biology, Am. J. Physiol. Endocrinol. Metab. 304 (2013) E789–799.
[54] H. Ikeuchi, Y.M. Ahn, T. Otokawa, B. Watanabe, L. Hegazy, J. Hiratake, et al., A sulfoximine-based inhibitor of human asparagine synthetase kills L-asparaginase- resistant leukemia cells, Bioorg. Med. Chem. 20 (2012) 5915–5927.
[55] S. Hettmer, A.C. Schinzel, D. Tchessalova, M. Schneider, C.L. Parker, R.T. Bronson, et al., Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma, Elife 4 (2015), e09436.
[56] C. Hodakoski, B.D. Hopkins, G. Zhang, T. Su, Z. Cheng, R. Morris, et al., Rac- mediated macropinocytosis of extracellular protein promotes glucose independence in non-small cell lung cancer, Cancers (Basel) 11 (2019) 37.
[57] G. Redelman-Sidi, G. Iyer, D.B. Solit, M.S. Glickman, Oncogenic activation of Pak1- dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells, Canc. Res. 73 (2013) 1156–1167.
[58] H.P. Lin, B. Singla, P. Ghoshal, J.L. Faulkner, M. Cherian-Shaw, P.M. O’Connor, et al., Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs, Br. J. Pharmacol. 175 (2018) 3640–3655.
[59] C. Ramirez, A.D. Hauser, E.A. Vucic, D. Bar-Sagi, Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis, Nature 576 (2019) 477–481.
[60] W. Yao, J.L. Rose, W. Wang, S. Seth, H. Jiang, A. Taguchi, et al., Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer, Nature 568 (2019) 410–414.
論文の公開元へ
